Immune response to native NadA from Neisseria meningitidis and its expression in clinical isolates in Brazil

References

1. Anderson E. L, Bowers T, Mink C. M, Kennedy D. J, Belshe R. B, Harakeh H, Pais L, Holder P, Carlone G. M. 1994; Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect Immun 62:3391–3395
   [Google Scholar]
2. Blake M. S, Gotschlich E. C. 1986; Functional and immunological properties of pathogenic Neisseria surface proteins. In Bacterial Outer Membranes as Model Systems pp 377–400 Edited by Inoue M. New York: Wiley;
   [Google Scholar]
3. Boslego J, Garcia J, Cruz C. 11 other authors 1995; Efficacy, safety, and immunogenicity of a meningococcal group B (15 : P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 13:821–829 [CrossRef]
   [Google Scholar]
4. Comanducci M, Bambini S, Brunelli B. 12 other authors 2002; NadA, a novel vaccine candidate of Neisseria meningitidis . J Exp Med 195:1445–1454 [CrossRef]
   [Google Scholar]
5. Frasch C. E. 1995; Meningococcal vaccines. In Meningococcal Disease pp 245–283 Edited by Cartwright K. New York: Wiley;
   [Google Scholar]
6. Frasch C. E, Robbins J. D. 1978; Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model. J Exp Med 147:629–644 [CrossRef]
   [Google Scholar]
7. Frasch C. E, Zollinger W. D, Poolman J. T. 1985; Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis 7:504–510 [CrossRef]
   [Google Scholar]
8. Fukasawa L. O, Gorla M. C. O, Schenkman R. P. F, Garcia L. R, Carneiro S. M, Raw I, Tanizaki M. M. 1999; Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate. Vaccine 17:2951–2958 [CrossRef]
   [Google Scholar]
9. Fukasawa L. O, Gorla M. C. O, Lemos A. P, Brandileone M. C, Schenkman R. P. F, Frasch C. E, Raw I, Tanizaki M. M. 2000; A 190 kDa conserved surface protein from Neisseria meningitidis that induces bactericidal antibodies. In Abstract Book of the Twelfth International Pathogenic Neisseria Conference Galveston, TX, USA:
   [Google Scholar]
10. Granoff D. M, Gupta R. K, Belshe R. B, Anderson E. L. 1998; Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 178:870–874 [CrossRef]
    [Google Scholar]
11. Kearney J. F, Radbruch A, Liesegang B, Rajewsky K. 1979; A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 123:1548–1550
    [Google Scholar]
12. Martin D, Cadieux N, Hamel J, Brodeur B. R. 1997; Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med 185:1173–1183 [CrossRef]
    [Google Scholar]
13. Maslanka S. E, Gheesling L. L, Libutti D. E. 14 other authors 1997; Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 4:156–167
    [Google Scholar]
14. Milagres L. G, Ramos S. R, Sacchi C. T, Melles C. E, Vieira V. S, Sato H, Brito G. S, Moraes J. C, Frasch C. E. 1994; Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun 62:4419–4424
    [Google Scholar]
15. Pizza M, Scarlato V, Masignani V. 33 other authors 2000; Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287:1816–1820 [CrossRef]
    [Google Scholar]
16. Poolman J. T. 1995; Development of a meningococcal vaccine. Infect Agents Dis 4:13–28
    [Google Scholar]
17. Richmond P, Kaczmarski E, Borrow R, Findlow J, Clark S, McCann R, Hill J, Barker M, Miller E. 2000; Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 181:761–764 [CrossRef]
    [Google Scholar]
18. Rosenqvist E, Hoiby E. A, Wedege E, Kusecek E, Achtman M. 1993; The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J Infect Dis 167:1065–1073 [CrossRef]
    [Google Scholar]
19. Sacchi C. T, Lemos A. P, Popovic T. 8 other authors 2001; Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997–1998: overview and implications for vaccine development. J Clin Microbiol 39:2897–2903 [CrossRef]
    [Google Scholar]
20. Shevchenko A, Chernushevic I, Shevchenko A, Wilm M, Mann M. 2002; ‘De novo’ sequencing of peptides recovered from in-gel digested protein by nanoelectrospray tandem mass spectrometry. Mol Biotechnol 20:107–118 [CrossRef]
    [Google Scholar]
21. Twumasi P. A Jr, Kumah S, Leach A. 9 other authors 1995; A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 171:632–638 [CrossRef]
    [Google Scholar]
22. Wedege E, Froholm L. O. 1986; Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect Immun 51:571–578
    [Google Scholar]
23. Wedege E, Hoiby E. A, Rosenqvist E, Froholm L. O. 1990; Serotyping and subtyping of Neisseria meningitidis isolates by co-agglutination, dot-blotting and ELISA. J Med Microbiol 31:195–201 [CrossRef]
    [Google Scholar]
24. Zollinger W. D. 1997; New and improved vaccines against meningococcal disease. In New Generation Vaccines . pp 469–488 Edited by Levine M. M., Woodrow G. C., Kaper G. S., Cobon J. B. New York: Marcel Dekker;